Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
Top Cited Papers
- 2 August 2008
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 372 (9639), 646-655
- https://doi.org/10.1016/s0140-6736(08)61081-8
Abstract
No abstract availableFunding Information
- Bristol-Myers Squibb
This publication has 25 references indexed in Scilit:
- Effects of HIV Infection and Antiretroviral Therapy on the Heart and VasculatureCirculation, 2008
- Stability of antiretroviral regimens in patients with viral suppressionAIDS, 2008
- Patient preferences among third agent HIV medications: a US and German perspectiveAIDS Care, 2007
- Epidemiology of Human Immunodeficiency Virus in the United StatesClinical Microbiology Reviews, 2007
- Class of Antiretroviral Drugs and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2007
- The use of the Framingham equation to predict myocardial infarctions in HIV‐infected patients: comparison with observed events in the D:A:D StudyHIV Medicine, 2006
- Body Fat and Other Metabolic Effects of Atazanavir and Efavirenz, Each Administered in Combination with Zidovudine plus Lamivudine, in Antiretroviral- Naive HIV-Infected PatientsClinical Infectious Diseases, 2006
- Simplification Therapy with Once‐Daily Emtricitabine, Didanosine, and Efavirenz in HIV‐1–Infected Adults with Viral Suppression Receiving a Protease Inhibitor–Based Regimen: A Randomized TrialThe Journal of Infectious Diseases, 2005
- AtazanavirDrugs, 2005
- Baseline HIV‐1 RNA Level and CD4 Cell Count Predict Time to Loss of Virologic Response to Nelfinavir, but Not Lopinavir/Ritonavir, in Antiretroviral Therapy–Naive PatientsThe Journal of Infectious Diseases, 2004